TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2579953

Group type: EXPERIMENTAL
Intervention: Dextran 40 peroperatively plus 0.5 g aspirin a day for 10 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Heparin calcium 5000 iu subcutaneously plus dihydroergotamine (DHE) 0.5 mg intramuscularly for 10 days
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dextran/aspirin
Number of subjects: 83

Group type: COMPARATOR
Intervention: DHE/heparin
Number of subjects: 83
Study: 31895884

Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5% twice daily for 42 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thermal Pulsation Procedure (TPP)
Number of subjects: 50
Study: 30396189

Group type: EXPERIMENTAL
Intervention: Oral Health Program (OHP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Walking Exercise Program (WEP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 65
Study: 26614104

Group type: COMPARATOR
Intervention: Pneumatic Dilation (PD)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Laparoscopic Heller Myotomy (LHM)
Number of subjects: 201
Study: 24958410

Group type: EXPERIMENTAL
Intervention: Integrated cardiopulmonary sonography with standard treatment
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard treatment only (Control)
Number of subjects: 128
Study: 22972968

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 16077

Group type: COMPARATOR
Intervention: Comorbidities (congestive heart failure)
Number of subjects: 16077

Group type: COMPARATOR
Intervention: Leg pain
Number of subjects: 16077

Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 16077

Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 16077

Group type: COMPARATOR
Intervention: Time on study
Number of subjects: 16077
Study: 20551833

Group type: EXPERIMENTAL
Intervention: IFA-AN
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: IFA-VG
Number of subjects: 194
Study: 18280438

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16007101

Group type: EXPERIMENTAL
Intervention: G1 (150 microg/m2/day of Lenograstim starting on day 1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: G5 (150 microg/m2/day of Lenograstim starting on day 5)
Number of subjects: 240

Group type: COMPARATOR
Intervention: G0 (no Lenograstim)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: G1 and G5
Number of subjects: 240
Study: 14671611

Group type: COMPARATOR
Intervention: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 0
Study: 10831103

Group type: COMPARATOR
Intervention: 250-ppm-F NaF rinse
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1000-ppm-F NaF rinse
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 228-ppm-F two-solution rinse
Number of subjects: 7
Study: 8795596

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (AH; 200 mg daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 1321248

Group type: EXPERIMENTAL
Intervention: Lisinopril (5‐40mg/day, mean dose 11 mg/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-dose trichlormethiazide (2.0‐4.0 mg/day, mean dose 2.2 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lisinopril and low-dose trichlormethiazide
Number of subjects: 56
Study: 6427483

Group type: EXPERIMENTAL
Intervention: Long-term mitomycin C instillation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30891734

Group type: EXPERIMENTAL
Intervention: High-target mean arterial pressure of 70-80 mm Hg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Low-target mean arterial pressure of 40-50 mm Hg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: DWI-positive brain lesions
Number of subjects: 197
Study: 28061840

Group type: EXPERIMENTAL
Intervention: Empowerment program based on a behavior change protocol
Number of subjects: 238

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 238
Study: 27183343

Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alprazolam (ALP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo (PBO)
Number of subjects: 0
Study: 24251381

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) 30 mg/kg/day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22105798

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Carbomer gel
Number of subjects: 51
Study: 19252205

Group type: EXPERIMENTAL
Intervention: Accelerometry under MAT EO condition
Number of subjects: 21
Study: 17703832

Group type: EXPERIMENTAL
Intervention: Intravenous epoetin-delta (ED)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Epoetin-alpha (EA)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Epoetin-delta (ED) during open-label phase
Number of subjects: 752
Study: 15066066

Group type: EXPERIMENTAL
Intervention: Fall-prevention program implemented by residential care staff using existing resources, including a fall-risk assessment tool and strategies to address identified risks.
Number of subjects: 628

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Fall-prevention program
Number of subjects: 628
Study: 11549300

Group type: EXPERIMENTAL
Intervention: Modified release dipyridamole (200 mg b.i.d. p.o.)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 9476765

Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) injections
Number of subjects: 127

Group type: COMPARATOR
Intervention: Hypertonic saline-epinephrine (HSE) injections
Number of subjects: 127
Study: 7946231

Group type: EXPERIMENTAL
Intervention: Open-door rehabilitation treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard locked-ward treatment
Number of subjects: 43
Study: 3284483

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Number of subjects: 46

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 46
Study: 29912782

Group type: EXPERIMENTAL
Intervention: Cardiac shock-wave therapy (CSWT) in addition to optimal medical treatment (OMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy with sham procedure (OMT+placebo)
Number of subjects: 0
Study: 28938905

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg with sustained-release (SR) sarpogrelate 300 mg (Anplone®) once a day for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 100 mg with clopidogrel 75 mg once a day for six months
Number of subjects: 0
Study: 25525820

Group type: EXPERIMENTAL
Intervention: Surgery for trachomatous trichiasis (TT)
Number of subjects: 483
Study: 24687169

Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (500 mg) twice daily for 4 months
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo twice daily for 4 months
Number of subjects: 380
Study: 22851564

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice a day) plus gemcitabine (1,250 mg/m² on days 1 and 8) and cisplatin (75 mg/m² on day 1)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine (1,250 mg/m² on days 1 and 8) and cisplatin (75 mg/m² on day 1)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice a day)
Number of subjects: 904
Study: 19342529

Group type: EXPERIMENTAL
Intervention: ISBAR communication tool education (40 min session)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 85
Study: 17296390

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg in 4 cc saline) via electromotive drug administration
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (4 cc) via electromotive drug administration
Number of subjects: 42
Study: 15446646

Group type: EXPERIMENTAL
Intervention: Stress-management program (12 1-hr. sessions over 24 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo program (anthropometric measurements and lectures on nutrition)
Number of subjects: 20
Study: 11231393

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) staining
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Endoscopy with MB staining
Number of subjects: 9
Study: 9732153

Group type: EXPERIMENTAL
Intervention: 3-day oral itraconazole (200 mg daily)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single oral fluconazole (150 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 6-day intravaginal clotrimazole (100 mg daily)
Number of subjects: 150
Study: 8973028

Group type: EXPERIMENTAL
Intervention: Home visitation program combined with office intervention
Number of subjects: 0
Study: 12283426

Group type: EXPERIMENTAL
Intervention: gemeprost 1 mg pessaries
Number of subjects: 50

Group type: COMPARATOR
Intervention: PGE2 7.5 mg gel
Number of subjects: 50
Study: 6244920

Group type: EXPERIMENTAL
Intervention: Captopril (150 mg t.i.c.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril (150 mg t.i.c.) + Hydrochlorothiazide
Number of subjects: 20
Study: 30389229

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (400 mg/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 35
Study: 28143495

Group type: EXPERIMENTAL
Intervention: Structured SMBG with clinical review every 3 months
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Structured SMBG with additional monthly telecare support from a trained study nurse
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual diabetes care
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study: 25929840

Group type: EXPERIMENTAL
Intervention: Stepped care intervention package for depression (psychoeducation, activity scheduling, problem solving treatment, and medication for severe depression)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Care as usual with enhanced training on depression diagnosis and management
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 234
Study: 25961613

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer (GD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gluma Comfort Bond + Desensitizer (GCBD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU)
Number of subjects: 20
Study: 23440432

Group type: EXPERIMENTAL
Intervention: MRI at 3T
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional catheter angiography (CCA)
Number of subjects: 23
Study: 20824373

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study: 18053019

Group type: EXPERIMENTAL
Intervention: Indacaterol 50 microg via MDDPI
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Indacaterol 100 microg via MDDPI
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg via MDDPI
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg via MDDPI
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg via SDDPI
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study: 17109282

Group type: EXPERIMENTAL
Intervention: Intraventricular rt‐PA treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12698113

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 74
Study: 10700419

Group type: EXPERIMENTAL
Intervention: HPV DNA testing using Hybrid Capture II (HCII) assay
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: HPV DNA testing using Polymerase Chain Reaction (PCR) assays
Number of subjects: 642
Study: 9682530

Group type: EXPERIMENTAL
Intervention: Suppression instructions
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nonsuppression instructions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Violent film
Number of subjects: 72

Group type: COMPARATOR
Intervention: Humorous film
Number of subjects: 72

Group type: COMPARATOR
Intervention: Neutral film
Number of subjects: 72
Study: 7996391

Group type: EXPERIMENTAL
Intervention: Single oral doses of (+)-sotalol 50, 100, 200, and 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated oral doses of (+)-sotalol 200 mg twice daily for 6.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single intravenous doses of (+)-sotalol 1.0 and 1.5 mg kg-1
Number of subjects: 0
Study: 3069682

Group type: EXPERIMENTAL
Intervention: Acebutolol (200 mg twice a day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29397250

Group type: EXPERIMENTAL
Intervention: Composite cartilage perichondrium island (CCPI) graft
Number of subjects: 168

Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 168
Study: 27748235

Group type: EXPERIMENTAL
Intervention: Maternal zinc supplementation during pregnancy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Iron+folic acid without zinc (Control)
Number of subjects: 242
Study: 26166637

Group type: EXPERIMENTAL
Intervention: r-hFSH (Gonal F®) 150 IU subcutaneously three times a week for 3 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82
Study: 23823132

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 29
Study: 21659889

Group type: EXPERIMENTAL
Intervention: High-resistance circuit (HRC) training
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Traditional strength (TS) training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 18606983

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally once daily on days 1 to 21, every 28 days, for 52 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally
Number of subjects: 49
Study: 17641543

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 300 or 150 microg depending on hemoglobin concentration
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 221
Study: 14989559

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11053506

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 15832

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 15832

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15832
Study: 9469655

Group type: EXPERIMENTAL
Intervention: Alternating 3 Hz magnetic field (induction 0.1 mT) applied for 20 min
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 62
Study: 7912085

Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte count measurements
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Change in individual CD4 count
Number of subjects: 851
Study: 3354029

Group type: EXPERIMENTAL
Intervention: Nimodipine 240 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31211416

Group type: EXPERIMENTAL
Intervention: 200 μg of oral vitamin K2
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 400 μg of oral vitamin K2
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both vitamin K2 arms (200 μg and 400 μg)
Number of subjects: 95
Study: 28878702

Group type: EXPERIMENTAL
Intervention: Stigma-Stop serious game
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control group (unrelated video game)
Number of subjects: 552
Study: 26835855

Group type: EXPERIMENTAL
Intervention: Group intervention I (IG I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group intervention II (IG II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 22684211

Group type: EXPERIMENTAL
Intervention: Lumbar extension traction in addition to hot packs and interferential therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hot packs and interferential therapy
Number of subjects: 64
Study: 21362731

Group type: EXPERIMENTAL
Intervention: NL-CPAP(2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: NL-HFPPV
Number of subjects: 30
Study: 18434577

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 3
Study: 16527405

Group type: EXPERIMENTAL
Intervention: 30% l‐menthol in ethanol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ethanol (control)
Number of subjects: 39
Study: 14504920

Group type: EXPERIMENTAL
Intervention: Irinotecan 350 mg/m2 every 21 days (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irinotecan 175 mg/m2 days 1 and 10 every 21 days (Group B)
Number of subjects: 120
Study: 12545845

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment at a dose of 0.5 IU/(kg d) subcutaneously between days 3‐17 post‐burn
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9177518

Group type: EXPERIMENTAL
Intervention: CLOtest
Number of subjects: 102

Group type: COMPARATOR
Intervention: PyloriTek
Number of subjects: 102

Group type: COMPARATOR
Intervention: PyloriTek (scored at 1 h)
Number of subjects: 102
Study: 1524760

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3912616

Group type: EXPERIMENTAL
Intervention: Chemotherapy + tamoxifen (Group CH)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Chemotherapy only (Group C)
Number of subjects: 81
Study: 30706309

Group type: EXPERIMENTAL
Intervention: US-guided TAP block
Number of subjects: 92
Study: 30373835

Group type: EXPERIMENTAL
Intervention: Exposure to images of a racially diverse environmental organization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to images of a nondiverse environmental organization
Number of subjects: 0
Study: 26953999

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 25047263

Group type: EXPERIMENTAL
Intervention: Fluorotherapy with sodium fluoride (Elmex fluoride gel® 1.25%) administered once daily for 1 year
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (SG2) did not receive fluorotherapy
Number of subjects: 50
Study: 22115977

Group type: EXPERIMENTAL
Intervention: Cone beam CT imaging of the mandibular ramus and body in 10 patients (study group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine presurgical imaging in 10 patients (control group)
Number of subjects: 20
Study: 19674252

Group type: EXPERIMENTAL
Intervention: Endothelial antioxidant compounds (EAC) plus sildenafil (100 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sildenafil (100 mg) alone
Number of subjects: 53

Group type: COMPARATOR
Intervention: EAC alone
Number of subjects: 53
Study: 17652885

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (target LDL-C <70 mg/dl)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy (target LDL-C <100 mg/dl)
Number of subjects: 42
Study: 16146572

Group type: EXPERIMENTAL
Intervention: Inspiratory twitches using magnetic nerve stimulation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Expiratory twitches using magnetic nerve stimulation
Number of subjects: 21
Study: 12116689

Group type: EXPERIMENTAL
Intervention: Serum troponin I (Tnl) measurements at admission (Tnl-1) and after 8 hours (Tnl-2)
Number of subjects: 86
Study: 10424833

Group type: EXPERIMENTAL
Intervention: EuroQol EQ-5D
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark II
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: EuroQol instrument
Number of subjects: 561
Study: 7772628

Group type: EXPERIMENTAL
Intervention: ranitidine 100 mg twice daily intravenously from the day before operation until the third postoperative day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 42
Study: 2108646

Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with Eminase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7465140

Group type: EXPERIMENTAL
Intervention: 2.0 g cefamandole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 100
Study: 31809986

Group type: EXPERIMENTAL
Intervention: L2 penalized logistic regression
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Artificial neural network
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Random forest
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: AdaBoost
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: CatBoost
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Support vector machine
Number of subjects: 1328
Study: 31116169

Group type: EXPERIMENTAL
Intervention: Drill practice of key resuscitation phases
Number of subjects: 156

Group type: COMPARATOR
Intervention: Scrimmage practice with reflective debriefs
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both interventions (Drill and Scrimmage)
Number of subjects: 156
Study: 27846631

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study: 26277254

Group type: EXPERIMENTAL
Intervention: Pilates intervention (6 weeks)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Physiotherapy treatment alone (control group)
Number of subjects: 97
Study: 23061430

Group type: EXPERIMENTAL
Intervention: Modified remifentanil regimen
Number of subjects: 23

Group type: COMPARATOR
Intervention: Classical remifentanil regimen
Number of subjects: 23